Related Experiment Video
Updated: Feb 13, 2026

Autonomously Bioluminescent Mammalian Cells for Continuous and Real-time Monitoring of Cytotoxicity
Published on: October 28, 2013
The Importance of Continuous Monitoring in Identifying Bradycardia during Propranolol Treatment for Infantile
Yasuhiko Maki1,2, Hiroyuki Iijima1, Kazue Yoshida3
1Department of General Pediatrics & Interdisciplinary Medicine, National Center for Child Health and Development, Tokyo, Japan.
Insights
Continuous monitoring detects more bradycardia during propranolol treatment for infantile hemangioma (IH) than spot checks. Reducing propranolol dosage manages bradycardia effectively, ensuring positive IH outcomes.
Area of Science:
- Pediatric cardiology
- Dermatology
- Pharmacology
Background:
- Infantile hemangioma (IH) is a common vascular tumor in infants.
- Propranolol is a first-line treatment for IH, but can cause bradycardia.
- Current monitoring practices for propranolol-induced bradycardia vary.
Purpose of the Study:
- To compare continuous monitoring versus spot measurement for detecting bradycardia during propranolol therapy for IH.
- To explore management strategies for bradycardia in infants treated with propranolol.
Main Methods:
- Retrospective study with historic controls (n=106) of infants (0-1 year) treated with propranolol for IH.
- Comparison of spot-measurement group (n=49) vs. continuous-monitoring group (n=57).
- Bradycardia defined as heart rate <90/min for 20 minutes; adverse events recorded.
Main Results:
- Bradycardia occurred significantly more often in the continuous-monitoring group (21%) than the spot-measurement group (2%, p=0.003).
- Two of 12 infants with bradycardia in the continuous-monitoring group were symptomatic.
- All symptomatic infants improved with propranolol dose reduction, achieving favorable IH outcomes.
Conclusions:
- Continuous monitoring is more sensitive for detecting bradycardia during propranolol treatment for IH.
- Reducing propranolol dosage is an effective strategy to manage bradycardia while maintaining positive IH treatment outcomes.
Introduction:
To clarify whether continuous-monitoring can detect bradycardia during propranolol treatment for infantile hemangioma (IH) and explore management practices for patients with bradycardia.
Methods:
This retrospective study with historic controls was conducted on children with IH aged 0-1 year admitted for propranolol treatment at the National Center for Child Health and Development between October 2016 and July 2023. Patients were divided into two groups based on the monitoring method, namely, the spot-measurement group (October 2016 to August 2018) and the continuous-monitoring group (September 2018 to July 2023). Bradycardia was defined as a heart rate of <90/min lasting for 20 minutes. Patient data included clinical characteristics, propranolol dosage, and adverse effects (bradycardia, hypotension, and hypoglycemia). Statistical analyses were performed using Fisher's exact and Mann-Whitney U tests.
Results:
During the study period, 106 patients were admitted for propranolol therapy; 49 were in the spot-measurement group and 57 in the continuous-monitoring group. The frequency of bradycardia was significantly higher in the continuous-monitoring group than in the spot-measurement group (21% vs. 2%, p = 0.003). In the continuous-monitoring group, 2 of 12 patients with bradycardia were symptomatic. All patients experienced prompt resolution of symptoms with the reduction of propranolol dosage and had favorable outcomes for IH.
Conclusions:
Continuous-monitoring can detect bradycardia more effectively during propranolol treatment for IH than spot-measurement, and reducing the dosage of propranolol can lead to favorable outcomes for IH while minimizing the risk of bradycardia.
Related Concept Videos
Continuing Care
Continuity of a Function
Continuity Equation
The mass flow rate is expressed as:
Continuity Equation
Equation of Continuity
Properties of Continuous Functions

